News | Women's Health | July 21, 2015

Scientific study confirms reduced variation between exam results with automated density measurements

July 21, 2015 - Researchers at the University of Virginia (UVA) Health System have demonstrated that automated volumetric fibroglandular breast density measurement tools are more precise than area-based methods.  Results of the study, "Reliability of Automated Breast Density Measurements," recently featured in Radiology, suggest that with lower variability, volumetric breast density is well suited for inclusion in breast cancer risk models. The announcement was made at The Association for Medical Imaging Management (AHRA)'s 43rd annual meeting and exposition, July 19-22 in Las Vegas. 

"Breast density is increasingly being considered with other known risk factors to improve risk prediction in order to give women personalized knowledge to make decisions about screening. However, variability in assigned density category may result in changes in recommendations for adjuvant screening. Thus, for consistency, objectivity, and ease of use, breast density measurement ideally should be automated and accurate," said Jennifer Harvey, M.D., professor of radiology at the UVA School of Medicine. "The purpose of this study was to estimate the reliability of area-based methods and automated volumetric breast density measurements using repeated measures."

Thirty women undergoing screening mammography consented to undergo a repeated left craniocaudal examination performed by a second technologist in this prospective study. Breast density was measured by using both area-based and volumetric methods (Volpara software). Discrepancy between the first and second breast density measurements was obtained for each algorithm by subtracting the second measurement from the first and then analyzed with a random-effects model to derive limits of measurement agreement. 

Results of the study demonstrate that variability in a repeated measurement of breast density is highest for area-based measurement tools, standard deviation 3.32 percent (2.65-4.44). In contrast, precision was highest for automated volumetric breast density tools, such as VolparaDensity, standard deviation 0.99 percent (0.79-1.33).  

"The excellent reproducibility of automated breast density measurements indicates that they would be well suited for inclusion in a breast cancer risk model.  This is consistent with results we presented at the San Antonio Breast Cancer Symposium in December that showed that the addition of volumetric breast density improved breast cancer risk discrimination," Harvey added.

For more information: www.uvahealth.com


Related Content

News | Breast Imaging

July 29, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the ...

Time July 29, 2024
arrow
News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiology Business

July 25, 2024 — The radiology gender gap is decreasing, but there remains work to be done, according to an editorial ...

Time July 25, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
Subscribe Now